Cannabinoid R&D and clinical trial expert appointed to AusCann board

Latest News

Medical cannabis company AusCann (ASX:AC8) has announced the appointment of cannabinoid expert and medical executive, Dr Marcel Bonn-Miller, to its board as a non-executive director.

Dr Bonn-Miller will replace Bruce Linton as a nominee director for AusCann’s largest shareholder Canopy Growth. David Pryce, who acted as an alternate director for Mr Linton, has also resigned.

Dr Bonn-Miller is global clinical scientific director of Spectrum Therapeutics - the medical division of Canopy Growth.

He is a researcher and pharmaceutical executive, bringing over 18 years of extensive clinical research and development expertise in cannabinoid-products for medical use. He has received funding for 27 research grants, has published 140 peer-reviewed academic papers and has led or contributed to 19 clinical trials.

“We are delighted to welcome Marcel to the Board. As a worldwide expert in the clinical use of cannabinoid-based medicines and with a wealth of medical, product development and research experience, he is uniquely placed to assist the Board with his strategic vision going forward," said AusCann chairman Dr Mal Washer. 

“On behalf of the Board, I would also like to sincerely thank Bruce Linton and David Pryce for their invaluable guidance and contribution to the business since AusCann’s early listing days.

“We are committed to positioning AusCann as a trusted pharmaceutical company. Providing reliable and dose consistent cannabinoid-based pharmaceutical products to patients, whilst building awareness and acceptance in the medical community of their benefits and clinical outcomes is how we will succeed in our strategy, and improve patients’ quality of life.”